Minimum Stada Takeover Level Reached Just In Time By Bain And Cinven

18 Aug 2017

• By Sten Stovall

A last-minute surge in shareholder acceptances has pushed Bain and Cinven's €5.4bn takeover offer for Stada Arzneimittel over the finish line just in time.

Crossing the line in the nick of time, Bain and Cinven's revised offer for Stada Arzneimittel AGmet its August 16 midnight deadline for garnering the minimum level of acceptances needed from shareholders to give the private equity firms their takeover target – at their second attempt – for €5.4bn ($6.3bn).

Nidda Healthcare, the acquiring company of Bain and Cinven, said in a statement on Aug 18 that it had received acceptances representing "above 63%" of all outstanding shares of Stada and that "therefore the minimum

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Adalvo And Gedeon Richter Join Forces On Semaglutide

06 May 2025

• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.